KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Profit After Tax: 2016-2024

Historic Profit After Tax for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$73.9 million.

  • Amneal Pharmaceuticals' Profit After Tax rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.3 million, marking a year-over-year increase of 157.71%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.63% down from last year.
  • Amneal Pharmaceuticals' Profit After Tax amounted to -$73.9 million in FY2024, which was down 51.63% from -$48.7 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Profit After Tax ranged from a high of $68.6 million in FY2020 and a low of -$254.8 million during FY2022.
  • Over the past 3 years, Amneal Pharmaceuticals' median Profit After Tax value was -$73.9 million (recorded in 2024), while the average stood at -$125.8 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Profit After Tax skyrocketed by 111.36% in 2020, and later tumbled by 1,363.21% in 2022.
  • Amneal Pharmaceuticals' Profit After Tax (Yearly) stood at $68.6 million in 2020, then slumped by 70.59% to $20.2 million in 2021, then slumped by 1,363.21% to -$254.8 million in 2022, then spiked by 80.88% to -$48.7 million in 2023, then plummeted by 51.63% to -$73.9 million in 2024.